Drugs / SER-155
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06801067 | Jan 2025 → Jan 2027 expected | diarrheal disease, enterocolitis | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04995653 | Nov 2021 → Jul 2024 | disease related to hematopoietic stem cell transplant | Seres Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-07-08 | Seres Therapeutics, Inc. | Results Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment serestherapeutics.com ↗
Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced encouraging top-line results from an IST evaluating SER-155 in patients with irEC. |
| 2026-04-20 | Seres Therapeutics, Inc. | Results Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 serestherapeutics.com ↗
Data showed that administration of SER-155 induced a significant and durable shift in GI microbiome composition relative to placebo, characterized by high SER-155 species relative abundance. |
| 2025-01-13 | ChemRar Research and Development Institute, LLC | Regulatory Дайджест FDA (статусы Breakthrough therapy designation) — декабрь 2024 года chemrar.ru ↗
Американская биотехнологическая компания из Массачусетса Seres Therapeutics получила от FDA статус Breakthrough Therapy Designation для своей исследовательской программы SER-155, направленной на снижение инфекций кровотока (bloodstream infections, BSIs) у взрослых. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-08 | Seres Therapeutics, Inc. | Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment serestherapeutics.com ↗ |
| 2026-06-25 | Seres Therapeutics, Inc. | Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis serestherapeutics.com ↗ |
| 2026-04-20 | Seres Therapeutics, Inc. | Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026 serestherapeutics.com ↗ |
| 2025-01-13 | ChemRar Research and Development Institute, LLC | Дайджест FDA (статусы Breakthrough therapy designation) — декабрь 2024 года chemrar.ru ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SER-155 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06801067 ↗ |
| Modality | Other / unclassified | “Cultivated Multi-Strain Live Bacterial Therapeutic” NCT06801067 ↗ |
| Route | Oral | “encapsulated for oral administration” NCT06801067 ↗ |